Literature DB >> 6547166

Pharmacologic rationale for regional drug delivery.

J M Collins.   

Abstract

Regional drug delivery is an approach designed to improve the selectivity of chemotherapy. When compared with systemic drug administration, regional delivery can potentially increase drug concentrations at tumor sites and/or lower systemic drug exposure. Pharmacokinetic analysis can evaluate or even predict the relative advantage of regional drug delivery. Based on a quantitative analysis of regional drug delivery, some drugs and sites of delivery are more favorable than others. The formulas for the therapeutic advantage of intraarterial, intrathecal, and intraperitoneal delivery have a similar structure. The ratio of total body clearance of a drug to its regional exchange rate is the principal determinant of therapeutic advantage. Thus, the most favorable circumstances for regional delivery are the use of drugs with high total body clearances and/or sites of delivery with low exchange rates. Pharmacodynamic factors must also be considered for the overall assessment of regional delivery.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6547166     DOI: 10.1200/JCO.1984.2.5.498

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  77 in total

1.  Mixing during intravertebral arterial infusions in an in vitro model.

Authors:  Robert J Lutz; Kathy Warren; Frank Balis; Nicholas Patronas; Robert L Dedrick
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

2.  Pathological complete remission of advanced hepatocellular carcinoma with main portal vein tumor thrombosis by hepatic arterial infusion chemotherapy.

Authors:  Yong Gil Kim; Jong Ryul Eun; Tae Nyeun Kim; Heon Ju Lee; Jae Woon Kim; Jay Chun Chang; Sung Su Yun; Joon Hyuk Choi
Journal:  Gut Liver       Date:  2010-06-16       Impact factor: 4.519

3.  Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.

Authors:  Ioannis T Konstantinidis; Bas Groot Koerkamp; Richard K G Do; Mithat Gönen; Yuman Fong; Peter J Allen; Michael I D'Angelica; T Peter Kingham; Ronald P DeMatteo; David S Klimstra; Nancy E Kemeny; William R Jarnagin
Journal:  Cancer       Date:  2015-12-22       Impact factor: 6.860

Review 4.  Hepatic arterial chemotherapy for primary and metastatic liver cancers.

Authors:  W Ensminger
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 5.  Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapy.

Authors:  Andrew L Lewis; Matthew R Dreher
Journal:  J Control Release       Date:  2012-01-21       Impact factor: 9.776

6.  Regional targeting of bisantrene by directed intravascular precipitation.

Authors:  J S Kovach; M Buck; T Tsukamoto; A Odegaard; M M Lieber
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Extracorporeal hemofiltration: a model for decreasing systemic drug exposure with intra-arterial chemotherapy.

Authors:  R A Graham; Z H Siddik; D C Hohn
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Intra-arterial BCNU in the treatment of recurrent medulloblastoma.

Authors:  K Watne; B Hager; H Hirschberg
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

9.  Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies.

Authors:  Andrea Cercek; Taryn M Boucher; Jill S Gluskin; Ariel Aguiló; Joanne F Chou; Louise C Connell; Marinela Capanu; Diane Reidy-Lagunes; Michael D'Angelica; Nancy E Kemeny
Journal:  J Surg Oncol       Date:  2016-08-26       Impact factor: 3.454

10.  A case report and description of the pharmacokinetic behavior of intrapleurally instilled etoposide.

Authors:  J M Jones; E A Olman; M J Egorin; J Aisner
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.